Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:03:35 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Q:VERA - VERA THERAPEUTICS INC. - https://www.moscom.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VERA - Q0.422.50·23.650.123.56+0.914.01,354.231,07410,64022.69  23.65  22.48551.61  18.5318:36:59Jun 0915 min RT 2¢

Recent Trades - Last 10 of 10640
Time ETExPriceChangeVolume
18:36:59Q23.2150.56530
18:35:51Q23.110.4610
18:30:46Q23.560.9140
17:39:49Q23.560.9140
17:28:45Q23.500.85100
17:18:53Q23.490.8410
16:34:13Q23.110.469
16:20:31Q23.110.462
16:06:28Q23.560.9150
16:06:11Q23.560.91100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-09 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-04 16:05U:VERANews ReleaseVera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-06-03 06:30U:VERANews ReleaseVera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
2025-06-02 06:30U:VERANews ReleaseVera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
2025-05-09 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-06 08:00U:VERANews ReleaseVera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
2025-04-09 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-04-03 08:00U:VERANews ReleaseVera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
2025-03-11 16:28U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-27 08:00U:VERANews ReleaseVera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
2025-02-26 08:25U:VERANews ReleaseVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-13 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-14 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-13 07:00U:VERANews ReleaseVera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
2025-01-07 16:05U:VERANews ReleaseVera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-09 18:29U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-22 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-18 08:00U:VERANews ReleaseVera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
2024-11-11 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-11 08:00U:VERANews ReleaseVera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study